Detalles de la búsqueda
1.
A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
Pediatr Res
; 70(2): 186-91, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21522037
2.
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
Lancet Infect Dis
; 15(12): 1398-408, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26511956
3.
Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity.
Infect Dis Ther
; 3(2): 339-47, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25156956
4.
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Pediatr Infect Dis J
; 33(7): 703-9, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356256
Resultados
1 -
4
de 4
1
Próxima >
>>